AstraZeneca开设了北京AI驱动的研发中心,以促进毒品发现,深化其对中国的承诺。 AstraZeneca opened a Beijing AI-driven R&D center to boost drug discovery, deepening its China commitment.

AstraZeneca在北京生物公园(BioPark)开设了一个新的全球研发中心,全球第六家,中国第二家,目的是利用AI和北京的科学生态系统加速药物发现。 AstraZeneca opened a new global R&D center in Beijing’s BioPark, its sixth worldwide and second in China, aiming to accelerate drug discovery using AI and Beijing’s scientific ecosystem. 该中心将与其上海设施密切合作,并与当地医院、大学和生物技术公司建立伙伴关系。 The center will collaborate closely with its Shanghai facility and partner with local hospitals, universities, and biotech firms. 北京经济-技术开发区是包括辉瑞公司和萨诺菲公司在内的5 000多家生物制药公司的枢纽,自2025年以来,该区域已批准了两项创新药物和三项医疗装置。 Located in the Beijing Economic-Technological Development Area, a hub for over 5,000 biopharma companies including Pfizer and Sanofi, the region has approved two innovative drugs and three medical devices since 2025. 此举凸显了AstraZeneca对中国及全球健康创新的持续承诺。 The move underscores AstraZeneca’s ongoing commitment to China and global health innovation.